Lion raises $20M in series A

Cell therapy company Lion TCR Pte. Ltd. (Singapore) raised $20 million on May 27 in a series A round from undisclosed existing investors and new investors, including Yashang Capital and Westlake Ventures Capital.

The company is developing LioCyx, an autologous T cell therapy expressing an HBV-specific TCR. The candidate is in a Phase I/IIa trial to treat relapsed hepatocellular carcinoma (HCC) after liver transplantation. Lion plans to expand the trial to other HCC indications...